Refine
Has Fulltext
- yes (20)
Is part of the Bibliography
- yes (20)
Year of publication
Document Type
- Journal article (20)
Language
- English (20)
Keywords
- NAFLD (5)
- NASH (4)
- fatty liver disease (3)
- obesity (3)
- apoptosis (2)
- fibrosis (2)
- inflammation (2)
- intestine (2)
- 25-hydroxycholesterol 7 alpha-hydroxylase (1)
- ALiOS (1)
- Breath tests (1)
- Drug metabolism (1)
- Epstein-Barr virus-induced gene 2 (1)
- FIB-4 (1)
- GLP-1 (1)
- Glucose metabolism (1)
- HCV infection (1)
- Hepatitis C (1)
- Hepatitis C infection (1)
- IL28B (1)
- Lipid metabolism (1)
- Liver cirrhosis (1)
- M30 (1)
- NLRP3 (1)
- RYGB (1)
- SVR (1)
- T cells (1)
- Transport (1)
- Western diet (1)
- acute hypobaric hypoxia (1)
- anemia (1)
- antiviral treatment (1)
- autoantibodies (1)
- beta-oxidation (1)
- bile (1)
- biliary-tract cancer (1)
- biomarker (1)
- caspase activation (1)
- ceftriaxone (1)
- chemokines (1)
- cholesterol 25 hydroxylase (1)
- chylomicron (1)
- circulating micrornas (1)
- cirrhosis (1)
- cytotoxic T cells (1)
- drug-induced immune hemolytic anemia (1)
- epithelial-mesenchymal transition (1)
- expression (1)
- fat absorption (1)
- fatty liver (1)
- fibrosis progression (1)
- fine-needle-aspiration (1)
- gastric bypass (1)
- gastric emptying (1)
- growth-factor-receptor (1)
- gut–liver axis (1)
- hemolysis (1)
- hepatic stellate cells (1)
- hepatitis C virus (1)
- hepatocellular carcinoma (1)
- host genetics (1)
- human cholangiocellular carcinoma (1)
- human intrahepatic cholangiocarcinoma (1)
- immune cells (1)
- independent marker (1)
- induce cyclooxygenase-2 expression (1)
- inflammasome (1)
- injury (1)
- insulin (1)
- insulin signaling (1)
- interleukin 1 (1)
- interleukin 18 (1)
- keratin-18 (1)
- liraglutide (1)
- liver (1)
- liver diseases (1)
- mammalian genomics (1)
- miR-122 (1)
- micronuclei (1)
- mouse feeding model (1)
- mouse models DNA damage (1)
- nonalcoholic fatty liver disease (1)
- nucleoside transporter (1)
- oxidative stress (1)
- peptide tyrosine tyrosine (PYY) (1)
- peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) (1)
- primary biliary cholangitis (1)
- primary sclerosing cholangitis (1)
- protein kinase D2/PKD2/PRKD2 (1)
- psoriasis (1)
- ribavirin serum levels (1)
- second line therapy (1)
- stable isotope breath tests (1)
- steatosis (1)
- systemic therapy (1)
- treatment response (1)
- tyrosine-kinase inhibitor (1)
- ursodeoxycholic acid (1)
- vitamin D (1)
Institute
- Medizinische Klinik und Poliklinik II (19)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (2)
- Pathologisches Institut (2)
- Institut für Klinische Epidemiologie und Biometrie (1)
- Institut für Klinische Transfusionsmedizin und Hämotherapie (1)
- Institut für Molekulare Infektionsbiologie (1)
- Institut für Pharmakologie und Toxikologie (1)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (1)
- Medizinische Klinik und Poliklinik I (1)
- Rudolf-Virchow-Zentrum (1)
EU-Project number / Contract (GA) number
- 678119 (1)
Beneficial effects of vitamin D treatment in an obese mouse model of non-alcoholic steatohepatitis
(2019)
Serum vitamin D levels negatively correlate with obesity and associated disorders such as non-alcoholic steatohepatitis (NASH). However, the mechanisms linking low vitamin D (VD) status to disease progression are not completely understood. In this study, we analyzed the effect of VD treatment on NASH in mice. C57BL6/J mice were fed a high-fat/high-sugar diet (HFSD) containing low amounts of VD for 16 weeks to induce obesity, NASH and liver fibrosis. The effects of preventive and interventional VD treatment were studied on the level of liver histology and hepatic/intestinal gene expression. Interestingly, preventive and to a lesser extent also interventional VD treatment resulted in improvements of liver histology. This included a significant decrease of steatosis, a trend towards lower non-alcoholic fatty liver disease (NAFLD) activity score and a slight non-significant decrease of fibrosis in the preventive treatment group. In line with these changes, preventive VD treatment reduced the hepatic expression of lipogenic, inflammatory and pro-fibrotic genes. Notably, these beneficial effects occurred in conjunction with a reduction of intestinal inflammation. Together, our observations suggest that timely initiation of VD supplementation (preventive vs. interventional) is a critical determinant of treatment outcome in NASH. In the applied animal model, the improvements of liver histology occurred in conjunction with reduced inflammation in the gut, suggesting a potential relevance of vitamin D as a therapeutic agent acting on the gut–liver axis.